Menu
← Oncology Approval Tracker
FDA DECISION ·
Bynfezia Pen
octreotide acetate · Sun Pharmaceutical Industries
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Subcutaneous octreotide pen for severe diarrhea and flushing due to metastatic carcinoid tumors and profuse watery diarrhea from vasoactive intestinal peptide-secreting tumors. The pen also has a separate acromegaly indication.
LAMPGEN ANALYSIS
Why it matters
FDA reapproved the pen after rescinding its 2020 approval. The reapproval followed a new submission addressing manufacturing compliance.
What research teams should watch
Train patients on pen setup, dose measurement and disposal, and track symptom control and short-acting treatment use.
PRIMARY RECORDS